Drug Database
Back to search

Belgium· BE-AMP-SAM385901-00

Ivemend 150 mg

A aprepitant product containing fosaprepitant dimeglumine, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 17 of our 19 countries.

ATC A04AD12

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedIvemend 150 mgATCA04AD12REGISTER NO.BE-AMP-SAM385901-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about fosaprepitant dimeglumineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aprepitant is registered in 17 of 19 countries.

Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search aprepitant products by name

Aprepitant · ATC A04AD12

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aprepitant costs, country by country.

Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Aprepitant · price per daily dose (165 mg)

USD · FX 28 Sept 2026

  • US United States$157.48 (acquisition cost)
  • CH Switzerland$73.26
  • FR France$33.15
  • FI Finland$0.40
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Fosaprepitant Dimeglumine
Manufacturer
Merck Sharp & Dohme
Country
Belgium (BE)
ATC code
A04AD12
ATC class
Aprepitant
Defined daily dose
165 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    2752285

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

583 interactions on record for aprepitant.

Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aprepitant against other medicinesHow interaction checks work

Aprepitant · interactions on record

583 records

  • 73 severe
  • 380 moderate
  • 25 minor
  • 104 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • LonafarnibA16AX20severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aprepitant in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aprepitant products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Spain · Fosaprepitant Zentiva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5f989278-4786-4d75-b387-d258750ed5cb
GET /v1/drugs/5f989278-4786-4d75-b387-d258750ed5cb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ivemend 150 mg",
  "name_fr": "Ivemend 150 mg",
  "name_nl": "Ivemend 150 mg",
  "amp_code": "SAM385901-00",
  "strengths": [
    "150.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Fosaprepitant Dimeglumine",
    "Fosaprepitant",
    "Disodium Edetate",
    "Lactose",
    "Sodium Hydroxide",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Aprepitant",
  "authorisation_numbers": [
    "EU/1/07/437/003",
    "EU/1/07/437/004"
  ]
}
API referenceMCP serverPlans

See everything about aprepitant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console